Growing body of data on PD-L1 as a cancer biomarker spurs interest Working towards partnership for non-dilutive funding of the final confirmatory head and neck cancer Registration Study VIENNA, ...
Confirmatory Phase 3 Trial Designed to Support Commercialization of Multikine for Head and Neck Cancer Treatment Full enrollment expected by Q2 2026 with plans to seek early approval at that time ...
Shares of CEL-SCI Corporation (NYSE:CVM) surged 25% following the announcement of a new partnership with a prominent Saudi pharmaceutical firm to advance the regulatory and commercial rollout of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results